IPSC - NASDAQ

Century Therapeutics, Inc.

Century Therapeutics, Inc.

IPSCยทNASDAQ

$2.07

-5.5%
HealthcareBiotechnology

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$179.20M
EPS-0.1100
P/E Ratio-18.82
Earnings Date08/13/2026
Century Therapeutics, Inc.

Century Therapeutics, Inc. Fair Value Envelope

IPSC ยท NASDAQ

Our analysis suggests that IPSC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.07, this represents a potential HIDDEN relative to our calculated worth for Century Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $2.07

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$896.1M
+ Cash & Equivalents$61.9M
Firm Value-$834.2M
- Debt$43.6M
Equity Value-$877.8M
/ Shares Outstanding86,387,476B
DCF Value-$10
OVERVALUED BY 591%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$109.1M
-$114.6M
-$120.4M
-$126.5M
-$132.9M
-$139.6M
-$146.6M
-$154.0M
-$161.8M
-$169.9M
Maintenance CapEx
-$178.2K
-$187.1K
-$196.6K
-$206.5K
-$216.9K
-$227.9K
-$239.4K
-$251.5K
-$264.1K
-$277.5K
Owner Earnings
-$109.3M
-$114.8M
-$120.6M
-$126.7M
-$133.1M
-$139.8M
-$146.9M
-$154.3M
-$162.0M
-$170.2M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$101.2M
-$98.4M
-$95.7M
-$93.1M
-$90.6M
-$88.1M
-$85.7M
-$83.3M
-$81.1M
-$78.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IPSC research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.